Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2025)

Maze Therapeutics has reported Income from Continuing Operations over the past 2 years, most recently at 34568000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 16.87% to 34568000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 131120000.0 through Dec 2025, down 330.07% year-over-year, with the annual reading at 131120000.0 for FY2025, 351.04% down from the prior year.
  • Income from Continuing Operations was 34568000.0 for Q4 2025 at Maze Therapeutics, down from 30087000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 139056000.0 in Q2 2024 and troughed at 34568000.0 in Q4 2025.